Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-05-17
2011-05-17
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100, C424S196110
Reexamination Certificate
active
07943139
ABSTRACT:
A small peptide of 10 or 11 mers, when linked to an immunogenic moiety, can protect against naferious effects of Nef protein of HIV. The vaccine is not used to induce sterilizing immunity, but to block the ability of soluble Nef protein to induce apoptosis, and to therefore alleviate lymphocyte depletion and organ damage.
REFERENCES:
patent: 5705612 (1998-01-01), Alizon et al.
patent: 6020171 (2000-02-01), Saito et al.
patent: 7312305 (2007-12-01), Bond et al.
patent: 2001/0008627 (2001-07-01), Soll et al.
patent: 2003/0158134 (2003-08-01), Voss
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how can we make one?”, Nat. Med. Vacc. Suppl. 4(5):495-498.
Moore, J. P., and D. R. Burton, 1999, “HIV-1 neutralizing antibodies: How full is the bottle?”, Nat. Med. 5(2):142-144.
Nabel, G. J., 2001, “Challenges and opportunities for development of an AIDS vaccine”, Nature 410:1002-1007.
Feinberg, M. B., and J. P. Moore, 2002, “AIDS vaccine models: Challenging challenge viruses”, Nat. Med. 8(3):207-210.
McMichael, A. J., and T. Hanke, 2003, “HIV vaccines 1983-2003”, Nat. Med. 9(7):874-880.
Altman, J. D., and M. B. Feinberg, 2004, “HIV escape: there and back again”, Nat. Med. 10(3):229-230.
Desrosiers, R. C., 2004, “Prospects for an AIDS vaccine”, Nat. Med. 10(3):221-223.
Pantaleo, G., and R. A. Koup, 2004, “Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know”, Nat. Med. 10(8):806-810.
Alimonti, J. B., et al., 2003, Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS, J. Gen. Virol. 84:1649-1661.
Lenardo, M. J., et al., 2002, Cytopathic killing of peripheral blood CD4+ T lymphocytes by human immunodeficiency virus type 1 appears necrotic rather than apoptotic and does not require env, J. Virol. 76(10):5082-5093.
Herbeuval, J.-P., and G. M. Shearer, 2007, HIV-1 immunopathogenesis: How good interferon turns bad, Clin. Immunol. 123:121-128.
Huang, J., et al. 2002. A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade. Immunol. Letters 84(3):205-209.
International Search Report, International Preliminary Report on Patentability and the Written Opinion of the International Search Authority for PCT/US2005/070041.
Bond Vincent C.
Huang Ming Bo
James Cleve
Powel Michael
Andrews & Kurth LLP
Morehouse School of Medicine
Parkin Jeffrey
Wang Ping
LandOfFree
Methods of generating a humoral immune response against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of generating a humoral immune response against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of generating a humoral immune response against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2643358